Complementing our in-house expertise with the know-how of excellent partners beyond Bayer - from academia and industry to startups - is an integral part of driving innovation impact at Bayer.
We understand that there is no Innovation without Collaboration which is why we are tapping into the world’s innovation ecosystems – and plugging into the brightest within and beyond Bayer – to explore, discover, test and co-create leading customer-centric solutions. We are constantly searching for new technologies and creative approaches to develop more effective solutions in the fields of health and nutrition. Our Open Innovation Strategy follows a three-pronged approach, namely:?
Leveraging LifeHubs at global innovation hotspots
Driving Open innovation programs & partnering
Forging cutting-edge venturing activities
Bayer wants to reach out to the world's most creative and innovative minds.
Head of Corporate Innovation, R&D and Societal Engagement
Our LifeHubs – Springbord to Partnerships
With our network of?Bayer LifeHubs?at innovation hotspots across the globe we are catalyzing impactful solutions at the intersection of health and nutrition.
Our LifeHubs provide the perfect springboard to:
Incubate solutions through exploring new skills, technologies and business models?
Co-create impactful answers through collaboration with customers, entrepreneurs and innovators?
Partner with experts through strategic alliances that explore cutting edge technologies?
Connect with the community through networking, mentoring and societal enhancement events
Driving Open Innovation Programs & Partnering
Together with bright minds also beyond Bayer, we join forces to develop new therapeutic options for patients, as well as solutions to optimize agricultural output and effectiveness.
All in all, with our Open Innovation programs, we offer
Funding of novel ideas via our crowdsourcing G4 programs?
Co-working / lab space via our global network of CoLaborator programs?
Startup acceleration and collaboration via our G4A program?
By investing venture capital, we support up-and-coming companies in life sciences to explore disruptive technologies beyond our core. For this reason, the innovation initiative “Leaps by Bayer” has been established.
Leaps by Bayer is spearheading a movement to make paradigm-shifting advances in the life sciences – targeting the breakthroughs that could fundamentally change the world for the better. Across healthcare and agriculture, Leaps by Bayer is aiming to conquer ten huge challenges facing humanity. Some people call them impossible. We call them leaps. We feel it is our responsibility to set new benchmarks; to find the courage to begin where others resist; and to drive breakthrough innovation. And we will not do it alone: we will collaborate with the world’s smartest minds in biotech.
It’s an approach that helps Bayer accessing cutting-edge technologies which impacts human health as well as crop science. The operating model is unique and stands for building new companies in collaboration with third parties (such as biotech companies, venture capital funds or hedge funds). Leaps by Bayer is complementary to Bayer’s divisional R&D approach as it only works on new technologies with breakthrough potential that aren’t part of the Bayer R&D portfolio.
To tackle these challenges, Bayer has founded three new companies to access disruptive technologies and breakthrough innovation:
Casebia Therapeutics: The objective of Casebia is to research curative treatments for several rare human diseases in Hematology/Autoimmune by utilizing CRISPR/Cas-based DNA editing.?
BlueRock Therapeutics: The focus lies on research around pluripotent stem cell technologies with the defined objective to create breakthrough innovations to cure Parkinson’s and chronic heart failure.?
Joyn Bio: Initial efforts focus on nitrogen fixation to enhance sustainability in agriculture. Researchers will broadly explore application of beneficial microbes to plants for next generation solutions to agriculture’s biggest challenges.